-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DGJnDln0phop2MB6X87hrOgHmdTkic+Wl5m1f3lA2Iude8PqLwz+wJiDBOkyUuqL RCZHtoXb9mmTvE7vuTO47w== 0000950142-06-001747.txt : 20060921 0000950142-06-001747.hdr.sgml : 20060921 20060921165246 ACCESSION NUMBER: 0000950142-06-001747 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20060921 DATE AS OF CHANGE: 20060921 GROUP MEMBERS: AISLING CAPITAL II, L.P. GROUP MEMBERS: AISLING CAPITAL PARTNERS LLC GROUP MEMBERS: AISLING CAPITAL PARTNERS, LP GROUP MEMBERS: ANDREW SCHIFF GROUP MEMBERS: DENNIS PURCELL GROUP MEMBERS: STEVE ELMS FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Aisling Capital II LP CENTRAL INDEX KEY: 0001350778 IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 88 SEVENTH AVE 30TH FL CITY: NEW YORK STATE: NY ZIP: 10106 MAIL ADDRESS: STREET 1: 88 SEVENTH AVE 30TH FL CITY: NEW YORK STATE: NY ZIP: 10106 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: INTERPHARM HOLDINGS INC CENTRAL INDEX KEY: 0000893970 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133673965 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-59847 FILM NUMBER: 061102563 BUSINESS ADDRESS: STREET 1: 75 ADAMS AVENUE CITY: HAUPPAGUE STATE: NY ZIP: 11788 BUSINESS PHONE: 6319520214 FORMER COMPANY: FORMER CONFORMED NAME: ATEC GROUP INC DATE OF NAME CHANGE: 19951221 FORMER COMPANY: FORMER CONFORMED NAME: HILLSIDE BEDDING INC DATE OF NAME CHANGE: 19940719 FORMER COMPANY: FORMER CONFORMED NAME: NATIONAL HILLSIDE BEDDING CORP DATE OF NAME CHANGE: 19930115 SC 13G 1 sc13g_interpharm.txt SCEDULE 13G =============================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. _)* INTERPHARM HOLDINGS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 460588106 (CUSIP Number) SEPTEMBER 11, 2006 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b) [X] Rule 13d-1(c) [_] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the reminder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). =============================================================================== - --------------------- ------------------ CUSIP NO. 460588106 Schedule 13G Page 2 of 15 - --------------------- ------------------ - -------------------------------------------------------------------------------- 1. Name of Reporting Person: Aisling Capital II, LP S.S. or I.R.S. Identifica- tion No. of Above Person - -------------------------------------------------------------------------------- 2. Check the Appropriate Box (a) [_] if a Member of a Group (b) [X] - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization Delaware - -------------------------------------------------------------------------------- Number of 5. Sole Voting Power: 7,330,617* Shares ------------------------------------------------ Beneficially 6. Shared Voting Power: -0- Owned By ------------------------------------------------ Each 7. Sole Dispositive Power: 7,330,617* Reporting ------------------------------------------------ Person 8. Shared Dispositive Power: -0- - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 7,330,617* - -------------------------------------------------------------------------------- 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares [_] - -------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row (9) 9.99%* - -------------------------------------------------------------------------------- 12. Type of Reporting Person PN - -------------------------------------------------------------------------------- - -------------------- * This amount is an approximation, which includes 2,281,914 shares of common stock issuable upon the exercise of warrants and approximately 5,048,703 shares of common stock issuable upon the initial conversion of 10,000 shares of Series C-1 Convertible Preferred Stock (the "Preferred Shares"). See Item 4(a). - --------------------- ------------------ CUSIP NO. 460588106 Schedule 13G Page 3 of 15 - --------------------- ------------------ - -------------------------------------------------------------------------------- 1. Name of Reporting Person: Aisling Capital Partners, LP S.S. or I.R.S. Identifica- tion No. of Above Person - -------------------------------------------------------------------------------- 2. Check the Appropriate Box (a) [_] if a Member of a Group (b) [X] - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization Delaware - -------------------------------------------------------------------------------- Number of 5. Sole Voting Power: 7,330,617* Shares ------------------------------------------------ Beneficially 6. Shared Voting Power: -0- Owned By ------------------------------------------------ Each 7. Sole Dispositive Power: 7,330,617* Reporting ------------------------------------------------ Person 8. Shared Dispositive Power: -0- - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 7,330,617* - -------------------------------------------------------------------------------- 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares [_] - -------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row (9) 9.99% - -------------------------------------------------------------------------------- 12. Type of Reporting Person PN - -------------------------------------------------------------------------------- - -------------------- * This amount is an approximation, which includes 2,281,914 shares of common stock issuable upon the exercise of warrants and approximately 5,048,703 shares of common stock issuable upon the initial conversion of the Preferred Shares. See Item 4(a). - --------------------- ------------------ CUSIP NO. 460588106 Schedule 13G Page 4 of 15 - --------------------- ------------------ - -------------------------------------------------------------------------------- 1. Name of Reporting Person: Aisling Capital Partners LLC S.S. or I.R.S. Identifica- tion No. of Above Person - -------------------------------------------------------------------------------- 2. Check the Appropriate Box (a) [_] if a Member of a Group (b) [X] - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization Delaware - -------------------------------------------------------------------------------- Number of 5. Sole Voting Power: 7,330,617* Shares ------------------------------------------------ Beneficially 6. Shared Voting Power: -0- Owned By ------------------------------------------------ Each 7. Sole Dispositive Power: 7,330,617* Reporting ------------------------------------------------ Person 8. Shared Dispositive Power: -0- - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 7,330,617* - -------------------------------------------------------------------------------- 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares [_] - -------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row (9) 9.99% - -------------------------------------------------------------------------------- 12. Type of Reporting Person OO - -------------------------------------------------------------------------------- - -------------------- * This amount is an approximation, which includes 2,281,914 shares of common stock issuable upon the exercise of warrants and approximately 5,048,703 shares of common stock issuable upon the initial conversion of the Preferred Shares. See Item 4(a). - --------------------- ------------------ CUSIP NO. 460588106 Schedule 13G Page 5 of 15 - --------------------- ------------------ - -------------------------------------------------------------------------------- 1. Name of Reporting Person: Steve Elms S.S. or I.R.S. Identifica- tion No. of Above Person - -------------------------------------------------------------------------------- 2. Check the Appropriate Box (a) [_] if a Member of a Group (b) [X] - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization United States - -------------------------------------------------------------------------------- Number of 5. Sole Voting Power: -0- Shares ------------------------------------------------ Beneficially 6. Shared Voting Power: 7,330,617* Owned By ------------------------------------------------ Each 7. Sole Dispositive Power: -0- Reporting ------------------------------------------------ Person 8. Shared Dispositive Power: 7,330,617* - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 7,330,617* - -------------------------------------------------------------------------------- 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares [_] - -------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row (9) 9.99% - -------------------------------------------------------------------------------- 12. Type of Reporting Person IN - -------------------------------------------------------------------------------- - -------------------- * This amount is an approximation, which includes 2,281,914 shares of common stock issuable upon the exercise of warrants and approximately 5,048,703 shares of common stock issuable upon the initial conversion of the Preferred Shares. See Item 4(a). - --------------------- ------------------ CUSIP NO. 460588106 Schedule 13G Page 6 of 15 - --------------------- ------------------ - -------------------------------------------------------------------------------- 1. Name of Reporting Person: Dennis Purcell S.S. or I.R.S. Identifica- tion No. of Above Person - -------------------------------------------------------------------------------- 2. Check the Appropriate Box (a) [_] if a Member of a Group (b) [X] - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization United States - -------------------------------------------------------------------------------- Number of 5. Sole Voting Power: -0- Shares ------------------------------------------------ Beneficially 6. Shared Voting Power: 7,330,617* Owned By ------------------------------------------------ Each 7. Sole Dispositive Power: -0- Reporting ------------------------------------------------ Person 8. Shared Dispositive Power: 7,330,617* - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 7,330,617* - -------------------------------------------------------------------------------- 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares [_] - -------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row (9) 9.99% - -------------------------------------------------------------------------------- 12. Type of Reporting Person IN - -------------------------------------------------------------------------------- - -------------------- * This amount is an approximation, which includes 2,281,914 shares of common stock issuable upon the exercise of warrants and approximately 5,048,703 shares of common stock issuable upon the initial conversion of the Preferred Shares. See Item 4(a). - --------------------- ------------------ CUSIP NO. 460588106 Schedule 13G Page 7 of 15 - --------------------- ------------------ - -------------------------------------------------------------------------------- 1. Name of Reporting Person: Andrew Schiff S.S. or I.R.S. Identifica- tion No. of Above Person - -------------------------------------------------------------------------------- 2. Check the Appropriate Box (a) [_] if a Member of a Group (b) [X] - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization United States - -------------------------------------------------------------------------------- Number of 5. Sole Voting Power: -0- Shares ------------------------------------------------ Beneficially 6. Shared Voting Power: 7,330,617* Owned By ------------------------------------------------ Each 7. Sole Dispositive Power: -0- Reporting ------------------------------------------------ Person 8. Shared Dispositive Power: 7,330,617* - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 7,330,617* - -------------------------------------------------------------------------------- 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares [_] - -------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row (9) 9.99% - -------------------------------------------------------------------------------- 12. Type of Reporting Person IN - -------------------------------------------------------------------------------- - -------------------- * This amount is an approximation, which includes 2,281,914 shares of common stock issuable upon the exercise of warrants and approximately 5,048,703 shares of common stock issuable upon the initial conversion of the Preferred Shares. See Item 4(a). - --------------------- ------------------ CUSIP NO. 460588106 Schedule 13G Page 8 of 15 - --------------------- ------------------ Item 1. (a) NAME OF ISSUER Interpharm Holdings, Inc. (the "Company"). (b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES 75 Adams Avenue Hauppage, NY 11788 Item 2. (a) NAMES OF PERSONS FILING This Statement is being filed on behalf of each of the following persons (collectively, the "Reporting Persons") (i) Aisling Capital II, LP, a Delaware limited partnership ("Aisling"); (ii) Aisling Capital Partners, LP, a Delaware limited partnership ("Aisling Partners" and general partner of Aisling); (iii) Aisling Capital Partners LLC, a Delaware limited liability company ("Aisling Partners GP" and general partner of Aisling Partners); (iv) Mr. Steve Elms ("Mr. Elms" and a managing member of Aisling Partners GP); (v) Mr. Dennis Purcell ("Mr. Purcell" and a managing member of Aisling Partners GP); and (vi) Mr. Andrew Schiff ("Mr. Schiff" and a managing member of Aisling Partners GP); (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE The address of the principal business offices of each of the Reporting Persons is 888 Seventh Avenue, 30th Floor, New York, NY 10106. (c) CITIZENSHIP (i) Aisling - a Delaware limited partnership (ii) Aisling Partners - a Delaware limited partnership (iii) Aisling Partners GP - a Delaware limited liability company (iv) Mr. Elms - United States (v) Mr. Purcell - United States (vi) Mr. Schiff - United States - --------------------- ------------------ CUSIP NO. 460588106 Schedule 13G Page 9 of 15 - --------------------- ------------------ (d) TITLE OF CLASS OF SECURITIES Common Stock, par value $0.01 per share (the "Common Stock" or "Shares") (e) CUSIP NUMBER 460588106 Item 3. This statement is not being filed pursuant to either Rule 13d-1(b) or 13d-2(b) or (c). Item 4. OWNERSHIP. (a) AMOUNT BENEFICIALLY OWNED: Each of the Reporting Persons may be deemed to beneficially own an aggregate of approximately 7,330,617 Shares, which includes 2,281,914 Shares issuable upon the exercise of warrants and approximately 5,048,703 Shares issuable upon the initial conversion of the Preferred Shares. The certificate of designations of the Preferred Shares provides that the holder of the Preferred Shares does not have the right to convert the Preferred Shares into Shares to the extent that such conversion would result in beneficial ownership by the holder of more than 9.99% of the number of Shares outstanding immediately after giving effect to such conversion. As a result of this provision, the Reporting Persons are reporting herein their beneficial ownership of the Shares representing 9.99% of the current outstanding Shares. If there was no such provision, as of the date hereof, the Reporting Persons would be able to own an additional 1,449,867 Shares issuable upon the initial conversion of the Preferred Shares held for the account of Aisling. (b) PERCENTAGE OWNED: Based on calculations made in accordance with Rule 13d-3(d), and there being 64,599,066 Shares outstanding as of September 11, 2006 each of the Reporting Persons may be deemed to beneficially own approximately 9.99% of the outstanding Common Stock. (c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS: (i) Each of Aisling, Aisling Partners and Aisling Partners GP may be deemed to have sole power to direct the voting and disposition of the 7,330,617 Shares beneficially owned by Aisling. (ii) By virtue of the relationships between and among the Reporting Persons as described in Item 2, each of the - --------------------- ------------------ CUSIP NO. 460588106 Schedule 13G Page 10 of 15 - --------------------- ------------------ Reporting Persons, other than Aisling, Aisling Partners and Aisling Partners GP, may be deemed to share the power to direct the voting and disposition of the 7,330,617 Shares beneficially owned by Aisling. Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS Not applicable. Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON The partners of Aisling have the right to participate in the receipt of dividends from, or proceeds from the sale of, the securities held for the account of Aisling in accordance with their ownership interests in Aisling. Item 7. IDENTIFICATION AND CLASSIFICATION OF SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY Not applicable. Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP Not applicable. Item 9. NOTICE OF DISSOLUTION OF GROUP Not applicable. Item 10. CERTIFICATION (b) The following certification shall be included if the statement is filed pursuant to ss.240.13d-1(c): By signing below we certify that, to the best of our knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] - --------------------- ------------------ CUSIP NO. 460588106 Schedule 13G Page 11 of 15 - --------------------- ------------------ SIGNATURES After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. Dated as of September 21, 2006 AISLING CAPITAL II, LP By: Aisling Capital Partners, LP General Partner By: Aisling Capital Partners LLC Managing Member By: /s/ Adele Kittredge Murray ------------------------------- Name: Adele Kittredge Murray Title: Secretary AISLING CAPITAL PARTNERS, LP By: Aisling Capital Partners LLC Managing Member By: /s/ Adele Kittredge Murray ------------------------------- Name: Adele Kittredge Murray Title: Secretary AISLING CAPITAL PARTNERS LLC By: /s/ Adele Kittredge Murray ------------------------------- Name: Adele Kittredge Murray Title: Secretary - --------------------- ------------------ CUSIP NO. 460588106 Schedule 13G Page 12 of 15 - --------------------- ------------------ /s/ Steve Elms ---------------------- Steve Elms /s/ Dennis Purcell ---------------------- Dennis Purcell /s/ Andrew Schiff ---------------------- Andrew Schiff - --------------------- ------------------ CUSIP NO. 460588106 Schedule 13G Page 13 of 15 - --------------------- ------------------ EXHIBIT INDEX Exhibit 1. Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended. EX-99 2 ex-1sc13g_interpharm.txt EXHIBIT 1 - --------------------- ------------------ CUSIP NO. 460588106 Schedule 13G Page 14 of 15 - --------------------- ------------------ EXHIBIT 1 --------- JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate. Dated as of September 21, 2006 AISLING CAPITAL II, LP By: Aisling Capital Partners, LP General Partner By: Aisling Capital Partners LLC Managing Member By: /s/ Adele Kittredge Murray ------------------------------- Name: Adele Kittredge Murray Title: Secretary AISLING CAPITAL PARTNERS, LP By: Aisling Capital Partners LLC Managing Member By: /s/ Adele Kittredge Murray ------------------------------- Name: Adele Kittredge Murray Title: Secretary - --------------------- ------------------ CUSIP NO. 460588106 Schedule 13G Page 15 of 15 - --------------------- ------------------ AISLING CAPITAL PARTNERS LLC By: /s/ Adele Kittredge Murray ------------------------------- Name: Adele Kittredge Murray Title: Secretary /s/ Steve Elms ------------------------------------- Steve Elms /s/ Dennis Purcell ------------------------------------- Dennis Purcell /s/ Andrew Schiff ------------------------------------- Andrew Schiff -----END PRIVACY-ENHANCED MESSAGE-----